Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TLDR
High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.About:
This article is published in The Lancet.The article was published on 2016-02-13 and is currently open access. It has received 363 citations till now. The article focuses on the topics: Standard treatment & Hydroxycarbamide.read more
Citations
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Book
Sickle Cell Disease
TL;DR: Studies from past decades related to such translational research as the use of hydroxyurea in treatment, as well as the therapeutic promise of red-cell ion-channel blockers, and antiadhesion and anti-inflammatory therapy are highlighted.
Journal ArticleDOI
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn Kleindorfer,Amytis Towfighi,Seemant Chaturvedi,Kevin M. Cockroft,Jose Gutierrez,Debbie Lombardi-Hill,Hooman Kamel,Walter N. Kernan,Steven J. Kittner,Enrique C. Leira,Olive Lennon,James F. Meschia,Thanh N. Nguyen,Peter M. Pollak,Pasquale Santangeli,Anjail Sharrief,Sidney C. Smith,Tanya N. Turan,Linda S. Williams +18 more
Journal ArticleDOI
Sickle cell disease
Gregory J. Kato,Frédéric B. Piel,Clarice D. Reid,Marilyn H. Gaston,Kwaku Ohene-Frempong,Lakshmanan Krishnamurti,Wally R. Smith,Julie A. Panepinto,David J. Weatherall,Fernando Ferreira Costa,Elliott Vichinsky +10 more
TL;DR: SCD is characterized by a remarkable phenotypic complexity; common acute complications are acute pain events, acute chest syndrome and stroke; chronic complications (including chronic kidney disease) can damage all organs.
References
More filters
Journal ArticleDOI
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
Samuel Charache,Michael L. Terrin,Richard D. Moore,George J. Dover,Franca B. Barton,Susan V. Eckert,Robert P. McMahon,Duane Bonds +7 more
TL;DR: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year and Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect.
Journal ArticleDOI
Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography
Robert J. Adams,Virgil McKie,Lewis L. Hsu,B Files,Elliott Vichinsky,Charles H. Pegelow,Miguel R. Abboud,Dianne Gallagher,Abdullah Kutlar,Fenwick T. Nichols,Duane Bonds,Donald Brambilla +11 more
TL;DR: Transfusion greatly reduces the risk of a first stroke in children with sickle cell anemia who have abnormal results on transcranial Doppler ultrasonography.
Journal ArticleDOI
Cerebrovascular Accidents in Sickle Cell Disease: Rates and Risk Factors
Kwaku Ohene-Frempong,Steven J. Weiner,Lynn A. Sleeper,Scott T. Miller,Stephen H. Embury,John W. Moohr,Doris L. Wethers,Charles H. Pegelow,Frances M. Gill +8 more
TL;DR: The highest rates of prevalence of CVA and incidence were in sickle cell anemia (SS) patients, but CVA occurred in all common genotypes, and the incidence of infarctive CVA was lowest in SS patients 20 to 29 years of age and higher in children and older patients.
Journal ArticleDOI
The use of transcranial ultrasonography to predict stroke in sickle cell disease
Robert J. Adams,Virgil McKie,Fenwick T. Nichols,Elizabeth Carl,Dao Long Zhang,K. McKie,Ramon Figueroa,Mark S. Litaker,William O. Thompson,David C. Hess +9 more
TL;DR: Transcranial ultrasonography can identify the children with sickle cell disease who are at highest risk for cerebral infarction and periodic ultrasound examinations and the selective use of transfusion therapy could make the primary prevention of stroke an achievable goal.
Journal ArticleDOI
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Winfred C. Wang,Russell E. Ware,Scott T. Miller,Rathi V. Iyer,James F. Casella,Caterina P. Minniti,Sohail Rana,Courtney D. Thornburg,Zora R. Rogers,Ram Kalpatthi,Julio C. Barredo,R. Clark Brown,Sharada A. Sarnaik,Thomas H. Howard,Lynn W. Wynn,Abdullah Kutlar,F. Daniel Armstrong,Beatrice Files,Jonathan C. Goldsmith,Myron A. Waclawiw,Xiangke Huang,Bruce W. Thompson +21 more
TL;DR: Hydroxycarbamide can now be considered for all very young children with sickle-cell anaemia, with some evidence for decreased acute chest syndrome, hospitalisation rates, and transfusion.
Related Papers (5)
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Barbara P. Yawn,George R. Buchanan,Araba Afenyi-Annan,Samir K. Ballas,Kathryn L. Hassell,Andra H. James,Lanetta B. Jordan,Sophie Lanzkron,Richard Lottenberg,William J. Savage,Paula Tanabe,Russell E. Ware,M. Hassan Murad,Jonathan C. Goldsmith,Jonathan C. Goldsmith,Eduardo Ortiz,Robinson Fulwood,Ann Horton,Joylene John-Sowah +18 more
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Winfred C. Wang,Russell E. Ware,Scott T. Miller,Rathi V. Iyer,James F. Casella,Caterina P. Minniti,Sohail Rana,Courtney D. Thornburg,Zora R. Rogers,Ram Kalpatthi,Julio C. Barredo,R. Clark Brown,Sharada A. Sarnaik,Thomas H. Howard,Lynn W. Wynn,Abdullah Kutlar,F. Daniel Armstrong,Beatrice Files,Jonathan C. Goldsmith,Myron A. Waclawiw,Xiangke Huang,Bruce W. Thompson +21 more